FDA clearance for Masimo’s OIRD detection puts Danaher in focus

Danaher (DHR) drew fresh attention after Masimo, one of its diagnostics businesses, received FDA 510(k) clearance for an opioid induced respiratory depression detection feature within the Radius VSM wearable patient monitor.

The new capability, built on Masimo’s smartSET sensor platform with AI driven pattern recognition, targets opioid related respiratory risks in hospitals and could reinforce Danaher’s positioning in connected, data rich monitoring across its Diagnostics segment.

At a share price of $197.93, Danaher has seen a 1-day share price return of 2.17% and a 30-day share price return of 6.05%, while its 1-year total shareholder return is down 1.87% and the 5-year total shareholder return is down 17.53%. This points to recent momentum against a weaker long term record as the market reassesses growth prospects and risks around developments like Masimo’s new OIRD capability.

If Masimo’s AI driven monitoring win has you thinking about where technology in healthcare can go next, it could be worth scanning other opportunities via the 40 healthcare AI stocks

With Danaher trading at $197.93 and reportedly sitting at a 24% discount to one analyst price target and an estimated intrinsic value, the question is simple: is there a mispriced opportunity here, or is the market already factoring in future growth?

Most Popular Narrative: 18.3% Undervalued

At $197.93, the most followed narrative on Danaher points to a fair value of $242.35, framing Masimo driven interest alongside a broader earnings and cash flow story.

The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that fair value gap for Danaher? The narrative focuses on recurring consumables, rising margins and a rich earnings profile. Curious which revenue mix and profit assumptions carry the most weight here? The full breakdown shows how those building blocks connect to the $242.35 figure, and which discount rate is doing the heavy lifting.

Result: Fair Value of $242.35 (UNDERVALUED)

However, there are still pressure points for Danaher, including weaker biotech and academic spending, as well as policy changes in China that could weigh on growth assumptions.

Another View: What Danaher’s P/E Is Telling You

The DCF work suggests Danaher is undervalued, but its P/E ratio tells a tighter story. At 38.1x earnings, the stock trades above its fair ratio of 30.1x and slightly above the global Life Sciences average of 37.4x. This points to less room for error if growth or margins disappoint.

Put simply, the market is already paying a premium versus where the fair ratio sits and only a touch higher than peers. Any setback in earnings expectations could bite faster than a DCF summary implies, raising the question of which signal you trust more at $197.93.

Next Steps

If the mixed signals on Danaher have you unsure which side to lean toward, this is the moment to review the data yourself and act on your own conviction, starting with the 3 key rewards

Looking for more investment ideas beyond Danaher?

If you want to pressure test your view on Danaher, comparing it with other stocks can sharpen your thinking and help you spot opportunities you might otherwise miss.

• Target potential mispricings by scanning 44 high quality undervalued stocks that combine solid fundamentals with room for a re rate.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores designed to highlight companies with steadier risk profiles.
• Hunt for under the radar potential using the screener containing 18 high quality undiscovered gems that most investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.